new glp-1 drug Medications for Weight Loss FDA says that the GLP-1

(2022) 16:824054/XML/NLM

Rodrigues, A

It often improves or helps prevent obesity-related diseases, including type 2 diabetes, sleep apnea, high blood pressure, and fatty liver disease

Simonsen et al used the Norwegian and Danish national health registries and found an increased risk of NAION development with semaglutide initiation (HR = 2.81)

Conclusions The study findings indicate that the use of GLP-1 receptor agonists is not associated with an increased risk of self-harm, suicidal ideation, and suicide as compared to DPP-4 and SGLT-2 inhibitors among T2D patients

Clinicians should also be cautious in the case of T2D patients receiving drugs that inhibit the renin-angiotensin system